Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the association of rheumatologists of Russia
E. L. Nasonov,A. M. Lila,Vadim I. Mazurov,B. S. Belov,A. E. Karateev,Tatiana Dubinina,O. A. Nikitinskaya,A. A. Baranov,Diana Abdulganieva,S. V. Moiseev,A. I. Zagrebneva +10 more
- Vol. 59, Iss: 3, pp 239-254
Reads0
Chats0
TLDR
The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.Citations
More filters
Journal ArticleDOI
Деплеция в-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (covid-19)
Е. Л. Насонов,А. С. Авдеева +1 more
TL;DR: According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.
Journal ArticleDOI
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
TL;DR: The frequency of exacerbation of RD after vaccination against COVID-19 seems to be quite low (5–7%) and has no significant associations with a specific vaccine or anti-rheumatic therapy, and unambiguous interpretation is difficult.
Journal ArticleDOI
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Evgeny Nasonov,T.V. Korotaeva +1 more
TL;DR: The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
Journal ArticleDOI
Rheumatoid arthritis and post-COVID-19 syndrome
TL;DR: It is thought that SARS-CoV-2 infection may be a trigger factor for new rheumatic musculoskeletal diseases, including rheumatoid arthritis or COVID-19 can unmask previously undetected RA, and arthritis in the post covid period may induce problems in differential diagnosis of rhematic diseases.
Journal ArticleDOI
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
TL;DR: Preliminary data suggest that vaccination against COVID-19 in patients with IRD appears to be quite safe, and further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of CO VID-19 immunization in rheumatic patients.
References
More filters
Journal ArticleDOI
Вакцинация при ревматических заболеваниях: союзник или противник?
TL;DR: The safety and immunogenicity of vaccination in preventing respiratory infections as the most common cause of an adverse outcome in rheumatic diseases is discussed.
Journal ArticleDOI
Вызывают ли нестероидные противовоспалительные препараты специфические осложнения при коронавирусной инфекции COVID-19?
TL;DR: There is no clear data indicating the risk of specific complications when using non-steroidal anti-inflammatory drugs (NSAIDs), and in particular ibuprofen, for COVID-19 infection, but when using NSAIDs in patients with acute respiratory viral diseases, keep in mind the possibility of class-specific complications from the gastrointestinal tract, cardiovascular system and kidneys.
Journal ArticleDOI
Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology
Lina María Saldarriaga Rivera,Daniel G. Fernández Ávila,Wilson Bautista Molano,Daniel Jaramillo Arroyave,Alain Jasaf Bautista Ramírez,Adriana Díaz Maldonado,Jorge Hernán Izquierdo,Edwin Jáuregui,María Constanza Latorre Muñoz,Juan Pablo Restrepo,Juan Sebastián Segura Charry +10 more
TL;DR: The recommendation for the majority of the pharmacological treatments used in rheumatology is to continue with immunomodulatory or immunosuppressive therapies in patients who do not have the infection, and to suspend it in patients with a diagnosis of SARS-CoV-2/COVID-19.